9月8日，Royalty Pharma盘前下跌5.72%，报60.61美元/股，成交额8.31万美元。
消息面上，标普500指数于上周五盘后公布最新季度调整结果。此前分析师Melissa Roberts将Royalty Pharma列为有望纳入标普500的候选企业之一，公司总市值约368亿美元，远高于227亿美元的最低纳入门槛。然而市场预期的纳入未能兑现，资金在盘后及周一盘前集中抛售，股价从上周五收盘价63.96美元大幅回落。
制药行业整体同步走弱，礼来跌0.36%，强生跌1.06%，辉瑞跌0.53%，默沙东跌0.73%，阿斯利康跌0.67%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.